Drug Profile
GSK 2245035
Alternative Names: GSK-2245035Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Immunomodulators; Interferon alfa 2a stimulants; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis
Most Recent Events
- 16 Oct 2018 GlaxoSmithKline withdraws a phase II trial in Allergic asthma prior to enrolment (NCT03707678)
- 04 May 2018 GlaxoSmithKline completes a phase II trial in Allergic asthma in Germany, United Kingdom (Intranasal) (EudraCT2015-005645-31) (NCT02833974)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-rhinitis in Netherlands (Intranasal, Spray)